Research programme: adenosine receptor antagonists - Corvus/Vernalis

Drug Profile

Research programme: adenosine receptor antagonists - Corvus/Vernalis

Alternative Names: Adenosine A2B receptor antagonist - Corvus/Vernalis; Immune checkpoint inhibitor B - Corvus/Vernalis; VER 4066; VER 4187; VER 6623; VER 6947; VER 7835

Latest Information Update: 16 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vernalis
  • Developer Corvus Pharmaceuticals; Vernalis
  • Class Purines; Pyrimidines; Thiophenes
  • Mechanism of Action Adenosine A2 receptor antagonists; Adenosine A2B receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer
  • Discontinued Anxiety disorders; Major depressive disorder

Most Recent Events

  • 10 Oct 2018 Vernalis has been acquired by Ligand Pharmaceuticals
  • 04 Jan 2016 Early research in Cancer in USA (unspecified route)
  • 12 Apr 2011 Biogen Idec terminates its licence for Adenosine A2A receptor antagonists
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top